Seizure Device Evaluated at Swedish Receives FDA Pre-Market Approval

November 21, 2013

FOR IMMEDIATE RELEASE: Nov. 21, 2013   

Contacts: Clay Holtzman, Swedish, 206-386-2748, clay.holtzman@swedish.org
                   Laura Allen – Swedish Epilepsy Center 206-320-3492

SEATTLE – The U.S. Food & Drug Administration has granted pre-market approval to a California company’s device for the treatment of medically refractory epilepsy that Swedish Neuroscience Institute played a key role in evaluating.

The NeuroPace® RNS® System, a treatment for adults with partial onset seizures that have not been controlled with two or more antiepileptic drugs, received FDA premarket approval on Nov. 14, 2013. Created by Mountain View, Calif.-based NeuroPace, the RNS System is a novel, implantable therapeutic device that delivers responsive neurostimulation, an advanced technolo...